Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
2.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

3.

The record on rosiglitazone and the risk of myocardial infarction.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jul 5;357(1):67-9. Epub 2007 Jun 5. No abstract available.

4.

Rosiglitazone and cardiovascular risk.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jun 14;356(24):2522-4. Epub 2007 May 21. No abstract available.

5.

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

Dahabreh IJ, Economopoulos K.

Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added].

PMID:
18375649
6.

Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.

Boyle P.

South Med J. 2007 Nov;100(11):1063-4. No abstract available.

PMID:
17984728
7.

Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.

Monami M, Marchionni N, Mannucci E.

Diabetes Res Clin Pract. 2008 Oct;82(1):48-57. doi: 10.1016/j.diabres.2008.08.002. Epub 2008 Sep 4.

PMID:
18775581
8.

Rosiglitazone and cardiovascular risk.

Diamond GA, Kaul S.

N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40. No abstract available.

PMID:
17806135
9.

The Avandia debacle: methodology and practical importance of the findings.

Meneghini LF, Florez H, Tamariz L.

South Med J. 2007 Nov;100(11):1062-3. No abstract available.

PMID:
17984727
10.

Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. Review.

PMID:
18706281
11.

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

Diamond GA, Bax L, Kaul S.

Ann Intern Med. 2007 Oct 16;147(8):578-81. Epub 2007 Aug 6.

PMID:
17679700
12.

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.

Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.

Am J Ther. 2008 Nov-Dec;15(6):506-11. doi: 10.1097/MJT.0b013e318167180c.

PMID:
19127132
13.

Rosiglitazone and cardiovascular risk.

Mannucci E, Monami M, Marchionni N.

N Engl J Med. 2007 Aug 30;357(9):938; author reply 939-40. No abstract available.

PMID:
17806136
14.

The Avandia debate: an unhappy conclusion.

Bloomgarden Z, Handelsman Y.

J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x. No abstract available.

15.

Rosiglitazone and cardiovascular risk.

Bracken MB.

N Engl J Med. 2007 Aug 30;357(9):937-8; author reply 939-40. No abstract available.

16.

FDA panel advises easing restrictions on rosiglitazone.

Tucker ME.

BMJ. 2013 Jun 10;346:f3769. doi: 10.1136/bmj.f3769. No abstract available.

PMID:
23752055
17.

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N.

Int J Cardiol. 2010 Aug 20;143(2):135-40. doi: 10.1016/j.ijcard.2009.01.064. Epub 2009 Mar 27.

PMID:
19328563
18.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group..

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

19.

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

Hiatt WR, Kaul S, Smith RJ.

N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. Epub 2013 Sep 2. No abstract available.

20.

Analytical issues regarding rosiglitazone meta-analysis.

Claggett B, Wei LJ.

Arch Intern Med. 2011 Jan 24;171(2):179-80; author reply 180. doi: 10.1001/archinternmed.2010.508. No abstract available.

PMID:
21263111

Supplemental Content

Support Center